INTRODUCTION
============

The prognosis of first-episode psychosis (FEP) is highly heterogeneous, ranging from sustained recovery to multiple recurrences and treatment resistance \[[@b1-pi-2019-06-20-1]\]. Approximately 25% of patients recover through initial treatment, whereas approximately 50% of patients experience a fluctuating course with recurrent exacerbation and remission of symptoms, and nearly 25% of patients are treatment refractory \[[@b2-pi-2019-06-20-1]\]. Despite these prognostic trajectories, clinicians have made great efforts to improve the prognosis of FEP patients by enlarging the percentage of the first and second groups. Previous studies have consistently shown that a better prognosis is related to a shorter duration of untreated psychosis (DUP), suggesting that the earlier introduction of antipsychotic treatment yields a better prognostic outcome \[[@b2-pi-2019-06-20-1]-[@b4-pi-2019-06-20-1]\]. Although antipsychotic medications can relieve the positive symptoms, prominent adverse effects, such as extrapyramidal symptoms or metabolic syndrome, reduce the quality of life as well as treatment adherence \[[@b5-pi-2019-06-20-1]-[@b7-pi-2019-06-20-1]\]. Therefore, predicting the prognosis from the FEP state would provide valuable information for both the clinicians and patients in deciding whether to provide less or more intensive treatment from the beginning of the intervention.

To date, efforts to predict the prognosis of FEP using clinical characteristics have not been successful enough \[[@b8-pi-2019-06-20-1],[@b9-pi-2019-06-20-1]\]. For example, Moos et al. \[[@b10-pi-2019-06-20-1]\] did not find any significant relationship between the global functional status of the patient at baseline and outcomes after 1 year of treatment. Moreover, Ayesa-Arriola et al. \[[@b11-pi-2019-06-20-1]\] showed that clinical, cognitive, and premorbid variables were not effective predictors of functional outcomes after a 3-year follow-up in patients with FEP. On the other hand, brain biomarkers related to prognostic outcomes have been suggested in many previous studies \[[@b12-pi-2019-06-20-1]\]. Lieberman et al. \[[@b13-pi-2019-06-20-1]\] showed that smaller brain volume loss during the disease course of FEP patients was related to better functional outcomes. In addition, Wood et al. \[[@b14-pi-2019-06-20-1]\] showed that a lower ratio of N-acetylaspartate (NAA) and choline-containing compounds to creatine and phosphocreatine (Cr) in the frontal cortex was associated with poorer functional outcomes after 1 year. A recent study by our group showed that a larger amplitude of the auditory P300 event-related potential (ERP) component measured at baseline predicted a better prognostic outcome after 1 year in patients with FEP \[[@b15-pi-2019-06-20-1]\]. The neural correlates of symptomatic or functional changes are more sensitive than the symptomatic approach alone and can reflect the underlying pathophysiologic mechanism. Therefore, efforts to find new brain biomarkers for predicting the prognosis of FEP would be important for both clinical practice and early psychosis research.

In this context, resting-state electroencephalography (EEG) can be a new brain biomarker for predicting the prognosis of FEP because EEG is a direct measure of electrical activities in the brain that are fundamental to neuronal communication. Furthermore, EEG has advantages for clinical application in that it is generally more applicable and less costly than brain imaging or ERP analysis. Quantitative analysis of resting-state EEG can provide the precise power of each EEG frequency to support the findings of their qualitative counterparts \[[@b16-pi-2019-06-20-1]\]. Previous studies have shown that the delta, theta, and beta frequency power was increased, but the alpha frequency power was decreased in patients with schizophrenia \[[@b17-pi-2019-06-20-1]\]. In FEP patients, the relationship of increased delta and theta frequency power to severe negative symptoms has been reported \[[@b18-pi-2019-06-20-1]\]. In particular, delta frequency power measured at frontal sites showed a correlation with negative symptom severity, suggesting that frontal delta power can be a putative biomarker for the negative symptoms of schizophrenia \[[@b19-pi-2019-06-20-1]\]. However, with regard to the prognosis prediction of FEP using resting-state EEG, only one study group has found that abnormal baseline oscillations in resting-state EEG were associated with poorer prognosis after 1-, 2-, 3-, and 5-year follow-up periods \[[@b20-pi-2019-06-20-1]-[@b23-pi-2019-06-20-1]\]. Unfortunately, these studies defined abnormalities in resting-state EEG oscillations based on qualitative readings of EEG data rather than using quantitative analyses of each frequency band, which can be used in general linear model analysis. Therefore, to the best of our knowledge, there has been no study to predict the symptomatic or functional outcome of FEP patients using resting-state EEG frequency powers.

In the current study, we aimed to investigate whether resting-state EEG spectral powers can predict symptomatic or functional improvement in patients with FEP after 1 year of usual treatment. In line with previous studies, we hypothesized that patients with FEP would show increased theta, delta, and beta frequency power and decreased alpha frequency power compared to healthy control (HC) subjects. We also expected that the altered frequency band power found in FEP patients could be a new biomarker to predict symptomatic or functional improvement during the 1-year follow-up period.

METHODS
=======

Participants
------------

In total, 24 patients with FEP and 24 age- and sex-matched HC subjects participated in this resting-state EEG study. FEP patients were enrolled from the inpatient and outpatient clinics of the Department of Neuropsychiatry at Seoul National University Hospital (SNUH). A patient with FEP was defined as a patient who was diagnosed with schizophreniform disorder, schizophrenia, or schizoaffective disorder using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Axis I Disorders (SCID-I) and whose duration of psychotic illness was no longer than 2 years. The clinical status of patients with FEP was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF) at the time of enrollment and reassessed after 1 year of usual treatment \[follow-up duration (days), mean 393, standard deviation 32, minimum length 347, maximum length 482\]. Medication use at baseline and during the follow-up period as well as the DUP was evaluated based on a thorough review of the medical records. The doses of antipsychotics and benzodiazepines were converted into an olanzapine-equivalent dose \[[@b24-pi-2019-06-20-1]\] and a lorazepam-equivalent dose \[[@b25-pi-2019-06-20-1]\], respectively. HC participants were recruited via an internet advertisement and confirmed to have no current and past psychiatric disorders and no family history of psychotic disorders. In both the FEP and HC groups, intelligence quotients (IQ) were examined using the Korean version of the Wechsler Adult Intelligence Scale \[[@b26-pi-2019-06-20-1]\], and handedness was assessed using the Annett Handedness Inventory \[[@b27-pi-2019-06-20-1]\]. Common exclusion criteria included a history of substance misuse (except nicotine), severe head trauma or neurological disorders, medical illness with cognitive sequelae, and intellectual disability (IQ\<70).

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital. Written informed consent was obtained from all of the participants after a full explanation of the study procedure was provided (H-1810-144-983).

EEG recording and processing
----------------------------

Participants were instructed not to drink coffee, tea or any other stimulant beverages and to refrain from cigarette smoking within the 2 hours before the recording session. The participants were seated in a comfortable single chair located in an isolated shield room with their eyes closed. Continuous EEG recordings were acquired for approximately 5 minutes using a Neuroscan 64 Channel SynAmps system equipped with a 64-channel Quick-Cap based on the modified international 10--20 system (Neuroscan, El Paso, TX, USA). Both mastoid sites were used as the reference. The EEG signals were digitized at a sampling rate of 1 kHz and online filtered between direct current (DC) and 100 Hz. Eye movement artifacts were monitored by the vertical and horizontal electrooculogram using electrodes below the left eye and near the outer canthus of the left eye. The impedances of all electrodes were less than 5 kΩ.

We used the EEGLAB toolbox to process the EEG data and to perform spectral analysis \[[@b28-pi-2019-06-20-1]\]. Bad channels were replaced via the linear interpolation of the adjacent channels (up to 7% per participant). The EEG data were filtered between 0.5 Hz to 50 Hz. Eye movement artifacts were reduced using the independent component analysis method with the 'sobi' algorithm implemented in the EEGLAB toolbox. By careful visual inspection, approximately 90 seconds of resting-state EEG data composed of stable epochs of 4 seconds without muscle and ocular movement artifacts was selected for spectral analysis. Selected epochs underwent fast Fourier transformations with a Hamming window, and the absolute power (μV^2^) of the delta (1.5--3.5 Hz), theta (4--7.5 Hz), alpha (8--14 Hz), and beta (14.5--30 Hz) frequency bands of each electrode were acquired. Arithmetic mean values of the absolute powers for each frequency band were obtained from grouped electrodes of frontal (FP1, FPz, FP2), centro-parietal (CP3, CPz, CP4), and posterior (PO7, POz, PO8, Oz) regions.

Statistical analysis
--------------------

The demographic and clinical characteristics of subjects were compared using independent samples t-tests for continuous variables and χ^2^ analysis for categorical data. To examine group differences in absolute spectral powers, repeated measures analysis of variance (ANOVA) was performed with the three grouped regions of electrode sites (frontal, centro-parietal, and posterior) as the within-subjects factor and group (FEP vs. HC) as the between-subjects factor. Because antipsychotic medication and benzodiazepines have been reported to be related to several quantitative electroencephalography (QEEG) frequency powers, the baseline olanzapine-equivalent dose of antipsychotics and lorazepam-equivalent dose of benzodiazepine were used as covariates \[[@b29-pi-2019-06-20-1]-[@b31-pi-2019-06-20-1]\]. After confirming the presence of significant group by region interactions, ANOVA with baseline olanzapine-equivalent dose of antipsychotics and lorazepam-equivalent dose of benzodiazepine as covariates was used to reveal specific regions showing group differences. A multiple regression analysis with the backward selection method was used to identify the factors that significantly predicted improvement in psychotic symptoms (i.e., PANSS scores at baseline minus those at the 1-year follow-up) and general functional status (i.e., GAF scores at the 1-year follow-up minus baseline scores) after a 1-year follow-up period with usual treatment. The anticipated predictive factors included absolute spectral power from regions showing significant group differences measured at baseline, demographic characteristics (age, sex, handedness, education years, IQ, DUP), mean daily olanzapine-equivalent dose of antipsychotics prescribed during the 1-year period, baseline PANSS positive or negative subscale scores, and baseline GAF scores. SPSS version 24 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis. The threshold for statistical significance was set at p\<0.05.

RESULTS
=======

Demographic and clinical characteristics
----------------------------------------

The demographic characteristics of the two groups (FEP and HC) at baseline and the clinical characteristics of the FEP group at baseline and after a 1-year follow-up are presented in [Table 1](#t1-pi-2019-06-20-1){ref-type="table"}. The distribution of age, sex, handedness and education years did not differ between groups. However, the FEP group showed a lower IQ score than the HC group (t=-4.828, p\<0.001). The mean DUP of the FEP group was 5.7 months, and there was no difference in the mean olanzapine-equivalent dose of antipsychotics used at baseline and at the 1-year follow-up in patients with FEP. The scores on PANSS and GAF showed significant improvements in psychotic symptoms and general functional status after 1 year compared to scores measured at baseline.

Quantitative electroencephalography (QEEG) results
--------------------------------------------------

[Figure 1](#f1-pi-2019-06-20-1){ref-type="fig"} shows two-dimensional topographic maps and a comparison of the absolute power of each frequency across the FEP and HC groups. A repeated measures ANOVA with baseline olanzapine-equivalent dose of antipsychotics and lorazepam-equivalent dose of benzodiazepine as covariates revealed a significant main effect of group (F=8.145, p=0.007), region (F=17.454, p\<0.001), and group by region interaction (F=3.362, p=0.039) in the absolute power of the delta frequency band. There was no significant group difference in the other frequency bands (i.e., theta, alpha, and beta). The results of ANCOVA to examine specific group differences in absolute spectral power in each region are summarized in [Table 2](#t2-pi-2019-06-20-1){ref-type="table"}. The delta absolute power in the frontal (F=7.586, p=0.009) and posterior (F=7.915, p=0.007) regions was significantly higher in patients with FEP than in HCs.

Multiple regression analysis results
------------------------------------

In the multiple regression analysis, improvement in positive symptoms was predicted by higher baseline delta power in the posterior region \[β=0.031, 95% confidence interval (CI)=0.002--0.059, p=0.036\] and higher baseline PANSS positive symptom subscale scores (β=0.851, 95% CI=0.618--1.083, p\<0.001). Lower baseline delta power in the frontal region (β=-0.025, 95% CI=-0.048-- -0.003, p=0.028), higher baseline PANSS negative symptom subscale scores (β=0.912, 95% CI=0.609--1.216, p\<0.001), and female sex (β=4.643, 95% CI=1.621--7.665, p=0.005) predicted later improvement in negative symptoms. Improvement in general functional status was predicted by decreased baseline delta power in the frontal region (β=-0.073, 95% CI=-0.138-- -0.009, p=0.027), increased baseline delta power in the posterior region (β=0.189, 95% CI=0.084--0.294, p=0.001), lower GAF scores at baseline (β=-1.135, 95% CI=-1.604---0.665, p\<0.001), and lower mean daily olanzapine-equivalent doses of antipsychotics used during the 1 year period (β=-0.096, 95% CI=-0.171-- -0.021, p=0.015)([Table 3](#t3-pi-2019-06-20-1){ref-type="table"}, [Figure 2](#f2-pi-2019-06-20-1){ref-type="fig"}).

DISCUSSION
==========

This study aimed to identify biological predictors of 1-year symptomatic and functional improvement in patients with FEP using quantitative analysis of resting-state EEG. We found that delta absolute power at the frontal and posterior regions was significantly increased in patients with FEP compared to HCs. Moreover, the altered power of the delta frequency band was a significant predictor of symptomatic and functional improvement after 1 year of usual treatment in FEP patients. Higher delta power in the posterior region and more severe positive symptoms at baseline predicted later improvement of positive symptoms. Improvement of negative symptoms was associated with lower delta power in the frontal region, higher negative symptoms at baseline, and female sex. In addition, better general functional status after 1 year was predicted by lower delta power in the frontal region, higher delta power in the posterior region, poorer functional status at baseline, and a lower dose of antipsychotic medication used over the 1-year period.

In line with previous studies, we found significantly higher delta power in patients with FEP compared to HCs \[[@b17-pi-2019-06-20-1],[@b32-pi-2019-06-20-1]\]. It has been shown that the increased delta power found in psychosis patients reflected the pathophysiology of the disorder itself and was not related to patient characteristics such as the duration of the illness or the result of antipsychotic treatment \[[@b33-pi-2019-06-20-1],[@b34-pi-2019-06-20-1]\]. Previous studies suggested that altered delta activity found in psychosis patients possibly arose from dopamine synthesis capacity in the fronto-striato-thalamic loops \[[@b17-pi-2019-06-20-1],[@b35-pi-2019-06-20-1],[@b36-pi-2019-06-20-1]\]. and promoted thalamic bursting \[[@b37-pi-2019-06-20-1]\], which is apparent from the beginning of psychotic disorder and is correlated with the severity of prodromal psychotic symptoms \[[@b35-pi-2019-06-20-1]\]. In addition, this delta activity has been suggested as a fundamental feature of the corticothalamic circuit \[[@b38-pi-2019-06-20-1]\]. Therefore, the increased delta power found in the current study may reflect the neurobiological correlate of the acute initiation of psychotic symptoms in FEP patients.

We found that decreased baseline delta power in the frontal region was associated with improvements in negative symptoms and general functioning after 1 year in patients with FEP. This finding is in line with previous studies that showed that increased delta power showed a positive correlation with higher scores on the PANSS negative subscale and was a marker for negative symptoms in patients with psychotic disorder \[[@b18-pi-2019-06-20-1],[@b19-pi-2019-06-20-1]\]. In addition, Saletu et al. \[[@b39-pi-2019-06-20-1]\] found that schizophrenia patients with predominant negative symptoms exhibited significantly increased delta activity in the frontal and bitemporal regions. These findings mostly refer to the cortical hypoactivation or hypofrontality found in patients with schizophrenia, as reflected in the reported correlation between increased delta activity at frontal regions and more severe negative symptoms as well as poorer general functional status \[[@b40-pi-2019-06-20-1]\].

Interestingly, in this study, delta power measured in the posterior region predicted improvements in psychotic symptoms and general functional status in an opposite manner relative to delta power measured in the frontal region. That is, increased baseline delta power in the posterior region predicted later improvement of positive symptoms and general functional status. The findings of delta power in the posterior site may be explained by the relationship between the reduced slow wave density and worse positive symptoms in patients with schizophrenia \[[@b41-pi-2019-06-20-1]\]. Moreover, the results of a study by Fryer et al. \[[@b42-pi-2019-06-20-1]\], which showed that decreased low-frequency oscillations in the posterior regions of the brain were related to greater symptomatic severity in both early schizophrenia patients and clinical high risk groups, further supports the results of the current study.

Because the response to antipsychotic medications, their adverse effects, and the prognosis of FEP patients varies \[[@b2-pi-2019-06-20-1],[@b5-pi-2019-06-20-1],[@b6-pi-2019-06-20-1]\], it is important to decide the intensity of an intervention from the beginning of the treatment that will improve quality of life and maintain treatment adherence. Therefore, predicting the prognosis from the beginning of the treatment would provide valuable information towards a personalized treatment that achieves better outcomes in FEP patients. Although attempts to predict the prognosis of FEP using various biomarkers such as brain imaging, ERPs, and brain neurochemistry has had impressive results \[[@b14-pi-2019-06-20-1],[@b15-pi-2019-06-20-1],[@b43-pi-2019-06-20-1]\], those modalities are expensive and labor-intensive methods for clinical application. In this context, resting-state EEG is a good candidate for clinical use due to its noninvasiveness, low cost, and easy application. In the current study, we found that the delta power of resting-state EEG predicted later improvement in psychotic symptoms and functional status. These results suggest that a quantitative analysis of resting-state EEG can be a putative biomarker to predict the prognosis of FEP and provide personalized treatment from the beginning of the treatment period in real clinical practice.

We must acknowledge several limitations of this study. First, the observational period was limited to a relatively short 1-year period to find improvements in negative symptoms or general functional status, which should be augmented by future studies with longer follow-up periods. Second, because all patients except one were medicated at the time of EEG assessment, we could not completely rule out medication effects, which may have biased the results. Although we tried to control for the dose of antipsychotics and benzodiazepines as covariates in the group comparison analyses, cautious interpretation is warranted. Third, EEG was measured only at baseline so that we could not show longitudinal changes in spectral powers in association with symptomatic or functional changes.

This study was the first to investigate whether the spectral power of resting-state EEG can be a predictive biomarker of a 1-year prognosis in FEP patients. Delta frequency power was increased in patients with FEP and predictive of symptomatic and functional improvements. The results of the current study not only suggest that delta frequency power is associated with pathophysiological mechanisms regardless of the duration of illness or medication effect but also elucidate the possibility of delta frequency power as a putative predictor of short-term prognosis from the beginning of a psychotic disorder. Using resting-state EEG, which is cost effective and easily applied in clinical practice, personalized medicine to optimize the intensity of acute and maintenance treatment for FEP patients would be further aided.
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![Group comparison results. A: Two-dimensional topographic maps of quantitative electroencephalography (QEEG) absolute power of each frequency band across patients with first-episode psychosis (FEP) and healthy control (HC) subjects. The color bar with numbers in the graph indicates QEEG absolute power (µV^2^). B: Group comparison of QEEG absolute power in delta, theta, alpha, and beta frequencies at the frontal, centroparietal, and posterior sites. The vertical lines indicate standard errors. ^\*^indicates that the mean difference is significant at the 0.05 level.](pi-2019-06-20-1f1){#f1-pi-2019-06-20-1}

![The partial correlations of the symptomatic and functional improvements in patients with first-episode psychosis (FEP) during the 1-year follow-up period with baseline delta absolute power in the frontal or posterior regions adjusted for controlling factors. PANSS: Positive and Negative Syndrome Scale, GAF: Global Assessment of Functioning.](pi-2019-06-20-1f2){#f2-pi-2019-06-20-1}

###### 

Demographic and clinical characteristics of patients with first-episode psychosis (FEP) at baseline and after 1 year of follow-up and healthy control (HC) subjects

                                                                         FEP (N=24)                   HC (N=24)                     Statistical analysis^[\*](#tfn1-pi-2019-06-20-1){ref-type="table-fn"}^                    
  ---------------------------------------------------------------------- ---------------------------- ----------------------------- ------------------------------------------------------------------------ ------- -------- ----------------------------------------------------------
  Age (years)                                                            22.4                         5.1                           22.8                                                                     4.2     -0.337   0.738
  Sex (male/female)                                                      10/14                        9/15                          0.087                                                                    0.768            
  Handedness (right/left)                                                22/2                         22/2                          0.000                                                                    1.000            
  Education (years)                                                      13.3                         2.1                           14.3                                                                     1.6     -1.921   0.061
  IQ                                                                     98.0                         13.7                          116.9                                                                    13.3    -4.828   \<0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
                                                                                                                                                                                                                              
                                                                         **FEP at baseline (N=24)**   **FEP after 1-year (N=24)**                                                                                             
                                                                                                                                                                                                                              
  DUP (months)                                                           5.7                          4.0                           \-                                                                       \-      \-       \-
  PANSS                                                                                                                                                                                                                       
   Total scores                                                          69.1                         14.0                          46.8                                                                     10.1    6.238    \<0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
  Positive symptoms                                                      17.3                         4.6                           10.2                                                                     2.6     6.923    \<0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
  Negative symptoms                                                      17.3                         4.6                           12.8                                                                     4.1     3.743    0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
  General symptoms                                                       34.5                         7.1                           23.8                                                                     5.0     5.678    \<0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
  GAF                                                                    45.3                         8.7                           66.9                                                                     10.6    -7.742   \<0.001^[‡](#tfn3-pi-2019-06-20-1){ref-type="table-fn"}^
  Antipsychotics dose^[†](#tfn2-pi-2019-06-20-1){ref-type="table-fn"}^   10.0                         8.3                           21.0                                                                     47.6    -1.381   0.181

an independent t-test or Welch's t-test was used if the variances were not equal; χ^2^ analysis or Fisher's exact test was used for categorical data; a paired samples t-test was used to compare values obtained at baseline and after 1 year in FEP patients,

olanzapine-equivalent dose of antipsychotics,

the mean difference is significant at the 0.005 level.

SD: standard deviation, IQ: intelligence quotient, DUP: duration of untreated psychosis, PANSS: Positive and Negative Syndrome Scale, GAF: Global Assessment of Functioning

###### 

Means and standard deviations (SDs) of electroencephalography (EEG) absolute spectral power in the frontal, centro-parietal, and posterior regions in patients with first-episode psychosis (FEP) and healthy control (HC) subjects

                            FEP (N=24)   HC (N=24)   Statistical analysis^[\*](#tfn4-pi-2019-06-20-1){ref-type="table-fn"}^                   
  ------------------------- ------------ ----------- ------------------------------------------------------------------------ ------- ------- --------------------------------------------------------
  Delta frequency                                                                                                                             
   Frontal region           93.5         69.8        68.4                                                                     33.6    7.586   0.009^[†](#tfn5-pi-2019-06-20-1){ref-type="table-fn"}^
   Centro-parietal region   72.1         28.8        65.4                                                                     32.5    1.427   0.239
   Posterior region         47.2         37.5        34.6                                                                     24.3    7.915   0.007^[†](#tfn5-pi-2019-06-20-1){ref-type="table-fn"}^
  Theta frequency                                                                                                                             
   Frontal region           62.7         26.0        68.8                                                                     52.1    0.013   0.908
   Centro-parietal region   67.9         29.7        65.5                                                                     43.6    0.220   0.642
   Posterior region         33.4         19.0        31.0                                                                     24.1    2.326   0.134
  Alpha frequency                                                                                                                             
   Frontal region           240.6        114.0       247.6                                                                    136.0   0.066   0.799
   Centro-parietal region   185.0        123.9       171.7                                                                    131.2   0.130   0.720
   Posterior region         185.0        123.9       171.7                                                                    131.2   2.762   0.104
  Beta frequency                                                                                                                              
   Frontal region           46.5         22.4        47.8                                                                     55.8    0.003   0.954
   Centro-parietal region   53.9         28.2        44.6                                                                     20.7    0.868   0.357
   Posterior region         38.3         18.6        33.4                                                                     22.4    2.636   0.112

analysis of variance with olanzapine-equivalent dose of antipsychotics and lorazepam-equivalent dose of benzodiazepine at baseline as covariates,

the mean difference is significant at the 0.05 level

###### 

Results of multiple regression analysis with the backward selection method to predict symptomatic and functional improvement in patients with first-episode psychosis (FEP)

  Outcome variables                                                      Significant predictors                R^2^     Beta     Standardized beta   p        95% CI   
  ---------------------------------------------------------------------- ------------------------------------- -------- -------- ------------------- -------- -------- --------
  Improvement in PANSS positive symptom subscale score                   Delta power in the posterior region   0.813    0.031    0.229               0.036    0.002    0.059
  Baseline PANSS positive symptom subscale score                                                               0.851    0.778    \<0.001             0.618    1.083    
  Improvement in PANSS negative symptom subscale score                   Delta power in the frontal region     0.754    -0.025   -0.302              0.028    -0.048   -0.003
  Baseline PANSS negative symptom subscale score                                                               0.912    0.716    \<0.001             0.609    1.216    
  Sex                                                                                                          4.643    0.397    0.005               1.621    7.665    
  Improvement in GAF                                                     Delta power in the frontal region     0.709    -0.073   -0.376              0.027    -0.138   -0.009
  Delta power in the posterior region                                                                          0.189    0.519    0.001               0.084    0.294    
  Baseline GAF score                                                                                           -1.135   0.224    \<0.001             -1.604   -0.665   
  Antipsychotic dose^[\*](#tfn6-pi-2019-06-20-1){ref-type="table-fn"}^                                         -0.096   -0.335   0.015               -0.171   -0.021   

mean daily olanzapine-equivalent dose of antipsychotics.

PANSS: Positive and Negative Syndrome Scale, GAF: Global Assessment of Functioning
